Thalidomide reduces tumour necrosis factor-α production by human alveolar macrophages

This publication has 22 references indexed in Scilit:

• The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures
  Clinical and Experimental Immunology, 1995
• Increased expression and occupancy of receptors for tumour necrosis factor on blood monocytes from tuberculosis patients
  Clinical and Experimental Immunology, 1993
• Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.
  The Journal of Experimental Medicine, 1993
• Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.
  The Journal of Experimental Medicine, 1991
• Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway.
  The Journal of Experimental Medicine, 1990
• Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis
  Nature, 1990
• Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.
  The Journal of Experimental Medicine, 1989
• The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection
  Cell, 1989
• Regulation of human lung fibroblast glycosaminoglycan production by recombinant interferons, tumor necrosis factor, and lymphotoxin.
  Journal of Clinical Investigation, 1988
• Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors.
  The Journal of Experimental Medicine, 1986